Evidence map›Paper›PMID 29991301›Full record

ArticleSLAS discovery : advancing life sciences R & D2018

Development of a High-Throughput Biochemical Assay to Screen for Inhibitors of Aerobactin Synthetase IucA.

Daniel C Bailey, Brian P Buckley, Mikhail V Chernov, Andrew M Gulick

Open access · bronzeAbstract read
In one paragraph

Article in SLAS discovery : advancing life sciences R & D, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. EfficientFrontiers in plant science · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Daniel C Bailey1 Department of Structural Biology, Jacobs School of Medicine & Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, USA.ORCID 0000-0003-4126-8700
Brian P Buckley3 Small Molecule Screening Shared Resource, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Mikhail V Chernov3 Small Molecule Screening Shared Resource, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Andrew M Gulick1 Department of Structural Biology, Jacobs School of Medicine & Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, USA.ORCID 0000-0003-4238-7453
Hauptman-Woodward Medical Research Institute · USRoswell Park Comprehensive Cancer Center · US

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
TRAINING IN MICROBIAL PATHOGENESIST32AI007614 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI READ, LAURIE K. · 1999 to 2015
$2.1M
Development of HTP Assay for Inhibitors of Aerobactin ProductionR01AI116998 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI GULICK, ANDREW M · 2016 to 2018
$1.4M
NCATS NIH HHS UL1 TR001412NIAID NIH HHS R01 AI116998NIAID NIH HHS T32 AI007614
6 · The paper itself

Abstract

Acquiring sufficient quantities of iron to support survival is often a critical limitation for pathogenic bacteria. To meet this demand, bacteria have evolved unique strategies to scavenge iron and circumvent the nutritional immunity exerted by their hosts. One common strategy, which is often a key virulence factor for bacterial pathogens, involves the synthesis, secretion, and reuptake of iron chelators known as siderophores. In vitro and in vivo studies have demonstrated that the siderophore aerobactin is critical for virulence in the hypervirulent pathotype of Klebsiella pneumoniae (hvKP). Given the high rate of multidrug resistance in K. pneumoniae, and in light of the ever-increasing demand for novel Gram-negative therapeutic targets, we identified aerobactin production as a promising antivirulence target in hvKP. Herein, we describe the development of a high-throughput biochemical assay for identifying inhibitors of the aerobactin synthetase IucA. The assay was employed to screen ~110,000 compounds across several commercially available small-molecule libraries. IucA inhibitors with activity at micromolar concentrations were identified in our screening campaigns and confirmed using secondary orthogonal assays. However, the most potent compounds also exhibited some properties commonly observed with promiscuous/nonspecific inhibitors, including incubation time and target enzyme concentration dependence, as well as the potential to antagonize unrelated enzymes.

Indexed as

Drug DiscoveryHigh-Throughput Screening AssaysAnti-Infective AgentsDose-Response Relationship, DrugEnzyme InhibitorsGene ExpressionGenes, ReporterHydroxamic AcidsOxo-Acid-Lyasesaerobactinaerobactin synthetaseAnti-Infective AgentsEnzyme InhibitorsHydroxamic AcidsOxo-Acid-Lyasesantibacterial drugsanti-infective drugsenzyme assays or enzyme kineticsprotein chemistryprotein labelingproteomics

Identifiers

PMID29991301
PMCPMC6246805
OpenAlexW2828958509

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.